The Plain Prescription Prices Act would require the Secretary of Health and Human Services, acting through CMS, to issue regulations within one year mandating that certain direct-to-consumer television advertisements for prescription drugs and biological products include a textual statement showing the product’s list price. The disclosure would have to be truthful and not misleading, and would reflect the list price for a typical 30-day regimen or typical course of treatment, as determined on the first day of the quarter in which the ad airs.
The bill applies to televised direct-to-consumer advertising, including broadcast, cable, streaming, and satellite television, for drugs and biologics covered under Medicare or Medicaid. It also directs CMS to decide whether the rule should extend to other forms of advertising, what the required statement should look like, how it should be enforced, and whether additional price information should be included. In effect, the bill creates a federal price-disclosure requirement aimed at prescription drug marketing rather than changing drug coverage or payment rules directly.
Impact
If enacted, the bill would add a new federal advertising disclosure requirement under the Social Security Act framework for prescription drugs and biological products paid for under Medicare and Medicaid. It would not itself set drug prices, but it would require CMS to regulate how list-price information is displayed in consumer-facing television ads and could lead to broader disclosure rules depending on the agency’s determinations. The measure would affect drug manufacturers and advertisers, and potentially consumers, by making price information more visible in pharmaceutical marketing.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or partisan division in the available record. Based on the bill’s purpose and bipartisan sponsorship, the measure appears to be framed as a consumer-transparency and affordability initiative, with an emphasis on helping viewers understand drug costs before seeking treatment. The overall tone of the bill is regulatory but not punitive, focusing on disclosure rather than price control.
Contention
The main points of potential contention are likely to be the scope and implementation of the disclosure requirement. The bill leaves CMS discretion to decide whether the rule should apply beyond television, what the statement must look like, how enforcement should work, and whether additional pricing details should be required. Opponents could argue that list prices may be misleading because they do not reflect insurance coverage, rebates, or patient out-of-pocket costs, while supporters are likely to favor the added transparency and pressure on high drug prices. Drug manufacturers and advertisers would be the primary regulated parties, while consumer advocates and transparency proponents would likely support the measure.
Enacting the prescription drug cost and affordability review act to establish the prescription drug pricing board and prescription drug affordability stakeholder council to review the cost of prescription medications and establish upper payment limits for certain prescription drugs.